Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Neoadjuvant therapy Clear all

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Paricalcitol, Hydroxychloroquine, Losartan, Neoadjuvant therapy and surgery only (Control); Combination Product · Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: conventional surgery, neoadjuvant therapy, thermal ablation therapy; Procedure
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 7
States / cities: Los Angeles, California • Orange, California • Coral Springs, Florida + 4 more

Conditions: Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Interventions: Nivolumab, Ipilimumab, Surgical Procedure, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Biological · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 132
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 74 more

Conditions: Colorectal Cancer
Interventions: FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound; Drug · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1048
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more

Conditions: Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
Interventions: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rectal Cancer
Interventions: M1 scheme, standard long course chemoradiotherapy; Other
Lead sponsor: University Medical Center Groningen; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Pembrolizumab, Folfirinox; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Neurofibrosarcoma, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery, 3-dimensional conformal radiation therapy, ifosfamide; Drug · Other · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 165
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 133 more

Conditions: Hepatitis C
Interventions: Ribavirin, Peg interferon alfa 2b, induction therapy; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions: gemcitabine hydrochloride, docetaxel, capecitabine, intensity-modulated radiation therapy, oxaliplatin, pancreatic surgical procedure, therapeutic conventional surgery, laboratory biomarker analysis; Drug · Radiation · Procedure + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: rituximab; Drug
Lead sponsor: Christopher Kane; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Melanoma
Interventions: Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System; Drug · Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Cladribine, Cytarabine, Decitabine, azacitidine or decitabine, Venetoclax; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Soft Tissue Sarcoma, Fibrous Histiocytoma, Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Synovial Sarcoma
Interventions: Bevacizumab, Radiation Therapy, Surgery; Drug · Radiation · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Transitional Cell Carcinoma of the Bladder
Interventions: Gemcitabine, Cisplatin, Sunitinib Malate, Radical Cystectomy; Drug · Procedure
Lead sponsor: Noah Hahn, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Gainesville, Florida • Indianapolis, Indiana • South Bend, Indiana + 1 more

Conditions: Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma
Interventions: Autologous DC Therapy; Biological
Lead sponsor: Diakonos Oncology Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: pembrolizumab, Low dose prostate radiation, Radical Prostatectomy; Drug · Radiation · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Colorectal Cancer, Liver Metastases
Interventions: Dupilumab, Toripalimab; Drug
Lead sponsor: Dan Feng; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Transplantation
Interventions: Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
Interventions: therapeutic conventional surgery, laboratory biomarker analysis, Axitinib, pharmacological study; Procedure · Other · Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Orange, California

Conditions: Breast Neoplasms
Interventions: Peripheral blood draw, Breast tissue collection, Bone marrow biopsy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Carcinoma
Interventions: Ultrasound Imaging; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 10
States / cities: Birmingham, Alabama • Denver, Colorado • New York, New York + 7 more

Conditions: Hepatocellular Carcinoma
Interventions: INCB099280; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

PHL Treatment in Pancreatic Cancer

Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER

Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Perioperative Therapy for Resectable Pancreatic Cancer

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Bevacizumab and Radiation Therapy for Sarcomas

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)